Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ --

  • Company remains focused on speeding innovation to patients and delivering greater value to customers.
  • Five strategic business units prepared to maximize growth opportunities in multiple therapeutic areas and geographies.
  • Lilly advances ranking to ninth in worldwide pharmaceutical sales; fastest growing top 10 pharma company in the U.S., major Europe and globally.
  • R&D pipeline boasts more than 60 molecules in clinical development, including 25 in Phases II and III.
  • Company expects 10 Phase III molecules in 2011, plans to launch 2 new medicines per year beginning in 2013.
  • Continued strong cash flow expected to fund R&D investment and business development transactions, while at least maintaining the current dividend.
  • 2010 EPS guidance set at $4.65 to $4.85, excluding the potential impact of health care reform in the U.S.
  • Longer-term guidance reconfirmed at low double-digit compound annual EPS growth between 2007 and 2011

At its annual meeting today with the investment community, Eli Lilly and Company (NYSE: LLY) highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

"In 2009, Lilly has once again exhibited strong performance in a tough environment, and we've continued with a series of actions aimed at speeding innovation to patients and delivering greater value to our customers," said John C. Lechle
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ... Report on China,s Ranibizumab Market, 2012-2019" report to ... approved by CFDA to treat wet age- related macular ... of Novartis, is available in the Chinese market. However, ... for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... MESA, Ariz., March 16, 2012 /PRNewswire/ -- On ... filed a collective action lawsuit against Sunovion Pharmaceuticals for failure ... are entitled under the Fair Labor Standards Act (FLSA). The Complaint ... District of Oregon on behalf of all Sunovion pharmaceutical reps ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation and autoimmune disorders, today provided an update ... VISTA-16 clinical study. Immediately after the ... clinical study, the Company took steps to cease patient ...
Cached Medicine Technology:JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals 2Anthera Provides Corporate Update on Recent Activities 2
(Date:8/28/2015)... ... 2015 , ... Northridge dentists Dr. Elyson and Dr. Assili are ... can currently receive a one hour treatment of this teeth whitening option. Zoom ... number of unique features that can turn teeth up to nine shades whiter. Effective ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout ... go deep sea diving. The act of recreational diving exposes the body ... reasons, it is vital that all recreational and professional divers undergo regular comprehensive ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Database have added comprehensive information on two new duals programs: Rhode Island ... 2015 launch; and Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... External Counterpulsation, ... Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with a ... Fit Clinic has been in business since 2007 helping people prevent and reverse ...
(Date:8/28/2015)... ... August 28, 2015 , ... A complimentary webinar offered ... Medicare & Medicaid Services’ (CMS) proposal to mandate bundled payments through the ... “Get Ready for Game Day: Comprehensive Care for Joint Replacement,” takes place at 12 ...
Breaking Medicine News(10 mins):Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3
... long way to go before they can claim to be new generation ... their kids, according to a survey. ,The UK survey ... nearly every change and 16 percent men argue every time over the ... expert, although some men argue about the job, it might help the ...
... face different treatment options and determining which ones to ... patients decisions regarding therapy for RA and glucosamine for ... to change their treatment as long as their condition ... trial results for glucosamine. ,Recent advances in ...
... cerebral palsy hampered Anthonys ability to walk. He and his ... would be confined to a wheelchair. ,As is ... disorder, Anthony was left with few options and his family ... finding answers to effectively address his condition. ,They ...
... marketing authorization for INVEGA(TM) (paliperidone prolonged release ... treatment of schizophrenia. This once-daily medication ... the active ingredient in INVEGA - through ... ,In clinical trials, INVEGA demonstrated significant ...
... affects learning have found that boys and girls are ... ,However, they have suggested that this ... from co-educational to segregated schools, or vice-versa. ... University in NSW, said that the key to this ...
... the first success in "decrypting" an enzyme's function from its ... drug discovery. ,Led by UCSF's Brian Shoichet, ... Frank Raushel of Texas A and M, the study offers ... many of the most successful drugs work by blocking enzyme ...
Cached Medicine News:Health News:Alternative Treatments for Arthritis 2Health News:Alternative Treatments for Arthritis 3Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 2Health News:Motion Analysis Helps Teen With Cerebral Palsy Regain Ability to Walk 3Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 2Health News:INVEGA(TM) Gets Marketing Authority from EU to Treat Schizophrenia 3Health News:Boys and Girls are Different by Nature and Learn in Different Ways 2Health News:"Decryption" of Enzyme's Functions Paves Way for Future Drug Discovery 2
... 50 Urine Chemistry Analyzer is designed for use ... time for technicians, allowing them to be more ... It has a throughput of 50 strips per ... results, which may be downloaded to a computer ...
... collection under vacuum process makes the ... reduction. ,The Optivac® Vacuum Mixing ... of continuous improvement since its original ... a consistently high-quality, homogenous cement, with ...
... 35 years, Palacos® Bone Cement has ... standard in cemented arthroplasty. Palacos® is ... gentamicin, providing an antibiotic loaded bone ... second stage of a two-stage revision ...
Occu-Flo Plugs Offer: , Easy Insertion , A polished, smooth, transparent finish which creates immediate patient comfort and adaptation , High tolerance by patients , No discomfort should removal be ...
Medicine Products: